Literature DB >> 8932329

Expression of the zinc finger gene EVI-1 in ovarian and other cancers.

D J Brooks1, S Woodward, F H Thompson, B Dos Santos, M Russell, J M Yang, X Y Guan, J Trent, D S Alberts, R Taetle.   

Abstract

The EVI-1 gene was originally detected as an ectopic viral insertion site and encodes a nuclear zinc finger DNA-binding protein. Previous studies showed restricted EVI-1 RNA or protein expression during ontogeny; in a kidney and an endometrial carcinoma cell line; and in normal murine oocytes and kidney cells. EVI-1 expression was also detected in a subset of acute myeloid leukaemias (AMLs) and myelodysplasia. Because EVI-1 is expressed in the urogenital tract during development, we examined ovarian cancers and normal ovaries for EVI-1 RNA expression using reverse transcription polymerase chain reaction (RT-PCR) and RNAase protection. Chromosome abnormalities were examined using karyotypes and whole chromosome 3 and 3q26 fluorescence in situ hybridisation (FISH). RNA from six primary ovarian tumours, five normal ovaries and 47 tumour cell lines (25 ovarian, seven melanoma, three prostate, seven breast and one each of bladder, endometrial, lung, epidermoid and histiocytic lymphoma) was studied. Five of six primary ovarian tumours, three of five normal ovaries and 22 of 25 ovarian cell lines expressed EVI-1 RNA. A variety of other non-haematological cancers also expressed EVI-1 RNA. Immunostaining of ovarian cancer cell lines revealed nuclear EVI-1 protein. In contrast, normal ovary stained primarily within oocytes and faintly in stroma. Primary ovarian tumours showed nuclear and intense, diffuse cytoplasmic staining. Quantitation of EVI-1 RNA, performed using RNAase protection, showed ovarian carcinoma cells expressed 0 to 40 times the EVI-1 RNA in normal ovary, and 0-6 times the levels in leukaemia cell lines. Southern analyses of ovarian carcinoma cell lines showed no amplification or rearrangements involving EVI-1. In some acute leukaemias, activation of EVI-1 transcription is associated with translocations involving 3q26, the site of the EVI-1 gene. Ovarian carcinoma karyotypes showed one line with quadruplication 3(q24q27), but no other clonal structural rearrangements involving 3q26. However, whole chromsome 3 and 3q26 FISH performed on lines with high EVI-1 expression showed translocations involving chromosome 3q26. EVI-1 is overexpressed in ovarian cancer compared with normal ovaries, suggesting a role for EVI-1 in solid tumour carcinogenesis or progression. Mechanisms underlying EVI-1 overexpression remain unclear, but may include rearrangements involving chromosome 3q26.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8932329      PMCID: PMC2074868          DOI: 10.1038/bjc.1996.583

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  49 in total

1.  Fluorescence in situ hybridization with human chromosome-specific libraries: detection of trisomy 21 and translocations of chromosome 4.

Authors:  D Pinkel; J Landegent; C Collins; J Fuscoe; R Segraves; J Lucas; J Gray
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

2.  Characterization of a human prostate adenocarcinoma cell line (DU 145) as a monolayer culture and as a solid tumor in athymic mice.

Authors:  D D Mickey; K R Stone; H Wunderli; G H Mickey; D F Paulson
Journal:  Prog Clin Biol Res       Date:  1980

3.  The use of avidin-biotin interaction in immunoenzymatic techniques.

Authors:  J L Guesdon; T Ternynck; S Avrameas
Journal:  J Histochem Cytochem       Date:  1979-08       Impact factor: 2.479

4.  Determination of cellular oncogene rearrangement or amplification in ovarian adenocarcinomas.

Authors:  D M Smith; D E Groff; R K Pokul; J L Bear; G Delgado
Journal:  Am J Obstet Gynecol       Date:  1989-10       Impact factor: 8.661

5.  Effects of anti-epidermal growth factor (EGF) receptor antibodies and an anti-EGF receptor recombinant-ricin A chain immunoconjugate on growth of human cells.

Authors:  R Taetle; J M Honeysett; L L Houston
Journal:  J Natl Cancer Inst       Date:  1988-09-07       Impact factor: 13.506

6.  Comparative properties of five human ovarian adenocarcinoma cell lines.

Authors:  R N Buick; R Pullano; J M Trent
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

7.  Amplification of 19q13.1-q13.2 sequences in ovarian cancer. G-band, FISH, and molecular studies.

Authors:  F H Thompson; M A Nelson; J M Trent; X Y Guan; Y Liu; J M Yang; J Emerson; L Adair; J Wymer; C Balfour; K Massey; R Weinstein; D S Alberts; R Taetle
Journal:  Cancer Genet Cytogenet       Date:  1996-03

8.  Comparison of four new cell lines from patients with adenocarcinoma of the ovary.

Authors:  L K Woods; R T Morgan; L A Quinn; G E Moore; T U Semple; K E Stedman
Journal:  Cancer Res       Date:  1979-11       Impact factor: 12.701

9.  Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cells.

Authors:  S B Rodan; K L Insogna; A M Vignery; A F Stewart; A E Broadus; S M D'Souza; D R Bertolini; G R Mundy; G A Rodan
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

10.  Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion.

Authors:  R P Warrell; C J Coonley; D J Straus; C W Young
Journal:  Cancer       Date:  1983-06-01       Impact factor: 6.860

View more
  27 in total

1.  Overexpression of Evi-1 oncoprotein represses TGF-β signaling in colorectal cancer.

Authors:  Xiyun Deng; Yanna Cao; Yan Liu; Fazhi Li; Kamalanathan Sambandam; Srinivasan Rajaraman; Archibald S Perkins; Alan P Fields; Mark R Hellmich; Courtney M Townsend; E Aubrey Thompson; Tien C Ko
Journal:  Mol Carcinog       Date:  2011-12-07       Impact factor: 4.784

2.  Direct interaction between the PRDM3 and PRDM16 tumor suppressors and the NuRD chromatin remodeling complex.

Authors:  Danton Ivanochko; Levon Halabelian; Elizabeth Henderson; Pavel Savitsky; Harshika Jain; Edyta Marcon; Shili Duan; Ashley Hutchinson; Alma Seitova; Dalia Barsyte-Lovejoy; Panagis Filippakopoulos; Jack Greenblatt; Evelyne Lima-Fernandes; Cheryl H Arrowsmith
Journal:  Nucleic Acids Res       Date:  2019-02-20       Impact factor: 16.971

3.  Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G0/1 phase.

Authors:  Kadin Karakaya; Friederike Herbst; Claudia Ball; Hanno Glimm; Alwin Krämer; Harald Löffler
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

4.  EVI1 oncoprotein interacts with a large and complex network of proteins and integrates signals through protein phosphorylation.

Authors:  Emilie A Bard-Chapeau; Jayantha Gunaratne; Pankaj Kumar; Belinda Q Chua; Julius Muller; Frederic A Bard; Walter Blackstock; Neal G Copeland; Nancy A Jenkins
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-15       Impact factor: 11.205

5.  Intratumoral Heterogeneity of Frameshift Mutations in MECOM Gene is Frequent in Colorectal Cancers with High Microsatellite Instability.

Authors:  Eun Ji Choi; Min Sung Kim; Sang Yong Song; Nam Jin Yoo; Sug Hyung Lee
Journal:  Pathol Oncol Res       Date:  2016-09-13       Impact factor: 3.201

6.  Expression and initial promoter characterization of PCAN1 in retinal tissue and prostate cell lines.

Authors:  D Cross; D J Reding; S A Salzman; K Q Zhang; W J Catalona; J Burke; J K Burmester
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

7.  Zinc finger transcription factor ecotropic viral integration site 1 is induced by all-trans retinoic acid (ATRA) and acts as a dual modulator of the ATRA response.

Authors:  Sonja C Bingemann; Torsten A Konrad; Rotraud Wieser
Journal:  FEBS J       Date:  2009-10-16       Impact factor: 5.542

8.  Molecular cytogenetics as a clinical test for prognostic and predictive biomarkers in newly diagnosed ovarian cancer.

Authors:  Shelly Gunn; Xavier Reveles; Korrie Weldon; Andres Barrera; Mariam Ishaque; Dale Taylor; Chris McCaskill; Jaeweon Kim; Rashmi Shah; Mansoor Mohammed; Todd Barry; Brianne Kaiser; Amita Patnaik; Anthony Tolcher
Journal:  J Ovarian Res       Date:  2013-01-04       Impact factor: 4.234

9.  Ecotropic viral integration site 1, a novel oncogene in prostate cancer.

Authors:  A Queisser; S Hagedorn; H Wang; T Schaefer; M Konantz; S Alavi; M Deng; W Vogel; A von Mässenhausen; G Kristiansen; S Duensing; J Kirfel; C Lengerke; S Perner
Journal:  Oncogene       Date:  2016-09-12       Impact factor: 9.867

10.  Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.

Authors:  Lovisa Osterberg; Kristina Levan; Karolina Partheen; Ulla Delle; Björn Olsson; Karin Sundfeldt; György Horvath
Journal:  BMC Cancer       Date:  2009-10-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.